Seeking Alpha

Morgan Stanley picks three biotechs worth buying: Biogen (BIIB), Celgene (CELG) and Gilead...

Morgan Stanley picks three biotechs worth buying: Biogen (BIIB), Celgene (CELG) and Gilead Sciences (GILD). The latter "offers 15-20% upside and the most attractive combination of fundamental positive drivers... 2012 events have the potential to meaningfully improve long-term cash flow visibility, driving multiple expansion and positive EPS revisions.”
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|